First, for some recurrent mutations, such as those from CTNNB1, CSF1R, JAK2, HRAS, and RUNX1, an exhaustive literature search showed that the clinical significance in breast carcinoma has rarely been addressed. This evidence concerns the gene HRAS and breast carcinoma.